Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer
Context: Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to MRONJ and the challenges associated with its management, prevention is crucial. Objective: We sought to evaluate the effectiveness of an...
Saved in:
Published in | The journal of clinical endocrinology and metabolism Vol. 100; no. 10; pp. 3887 - 3893 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Endocrine Society
01.10.2015
Copyright by The Endocrine Society |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Context:
Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to MRONJ and the challenges associated with its management, prevention is crucial.
Objective:
We sought to evaluate the effectiveness of an active dental intervention in reducing MRONJ incidence.
Design and Setting:
We identified all patients who received antiresorptive drug therapy at a specialized cancer center between January 2003 and December 2013 through hospital pharmacy records, whereas confirmed cases of MRONJ were identified through a hospital database.
Main Outcome Measures:
The incidence of MRONJ before and after the implementation of active dental intervention in July 2008 was quantified and compared.
Results:
A total of 1243 patients received antiresorptive drug therapy, with 34 confirmed cases of MRONJ (crude overall incidence, 2.7%). The incidence of MRONJ was significantly lower in patients who received antiresorptive therapy after the implementation of guidelines that emphasized active dental input (0.8 vs 4.6%; χ2 = 16.2; P = .00006). Using a binominal logistic regression model that adjusted for the number of doses of antiresorptive drug received, patients who received active dental input had an odds ratio of developing MRONJ of 0.24 (95% confidence interval, 0.09, 0.61; P = .004).
Conclusion:
The likelihood of developing MRONJ can be minimized through the implementation of prophylactic dental assessment and active dental intervention. This reinforces the importance of increased dental awareness and enhanced dental intervention in the prevention of MRONJ. |
---|---|
AbstractList | Context:
Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to MRONJ and the challenges associated with its management, prevention is crucial.
Objective:
We sought to evaluate the effectiveness of an active dental intervention in reducing MRONJ incidence.
Design and Setting:
We identified all patients who received antiresorptive drug therapy at a specialized cancer center between January 2003 and December 2013 through hospital pharmacy records, whereas confirmed cases of MRONJ were identified through a hospital database.
Main Outcome Measures:
The incidence of MRONJ before and after the implementation of active dental intervention in July 2008 was quantified and compared.
Results:
A total of 1243 patients received antiresorptive drug therapy, with 34 confirmed cases of MRONJ (crude overall incidence, 2.7%). The incidence of MRONJ was significantly lower in patients who received antiresorptive therapy after the implementation of guidelines that emphasized active dental input (0.8 vs 4.6%; χ2 = 16.2; P = .00006). Using a binominal logistic regression model that adjusted for the number of doses of antiresorptive drug received, patients who received active dental input had an odds ratio of developing MRONJ of 0.24 (95% confidence interval, 0.09, 0.61; P = .004).
Conclusion:
The likelihood of developing MRONJ can be minimized through the implementation of prophylactic dental assessment and active dental intervention. This reinforces the importance of increased dental awareness and enhanced dental intervention in the prevention of MRONJ. CONTEXT:Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to MRONJ and the challenges associated with its management, prevention is crucial. OBJECTIVE:We sought to evaluate the effectiveness of an active dental intervention in reducing MRONJ incidence. DESIGN AND SETTING:We identified all patients who received antiresorptive drug therapy at a specialized cancer center between January 2003 and December 2013 through hospital pharmacy records, whereas confirmed cases of MRONJ were identified through a hospital database. MAIN OUTCOME MEASURES:The incidence of MRONJ before and after the implementation of active dental intervention in July 2008 was quantified and compared. RESULTS:A total of 1243 patients received antiresorptive drug therapy, with 34 confirmed cases of MRONJ (crude overall incidence, 2.7%). The incidence of MRONJ was significantly lower in patients who received antiresorptive therapy after the implementation of guidelines that emphasized active dental input (0.8 vs 4.6%; χ = 16.2; P = .00006). Using a binominal logistic regression model that adjusted for the number of doses of antiresorptive drug received, patients who received active dental input had an odds ratio of developing MRONJ of 0.24 (95% confidence interval, 0.09, 0.61; P = .004). CONCLUSION:The likelihood of developing MRONJ can be minimized through the implementation of prophylactic dental assessment and active dental intervention. This reinforces the importance of increased dental awareness and enhanced dental intervention in the prevention of MRONJ. Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to MRONJ and the challenges associated with its management, prevention is crucial. We sought to evaluate the effectiveness of an active dental intervention in reducing MRONJ incidence. We identified all patients who received antiresorptive drug therapy at a specialized cancer center between January 2003 and December 2013 through hospital pharmacy records, whereas confirmed cases of MRONJ were identified through a hospital database. The incidence of MRONJ before and after the implementation of active dental intervention in July 2008 was quantified and compared. A total of 1243 patients received antiresorptive drug therapy, with 34 confirmed cases of MRONJ (crude overall incidence, 2.7%). The incidence of MRONJ was significantly lower in patients who received antiresorptive therapy after the implementation of guidelines that emphasized active dental input (0.8 vs 4.6%; χ(2) = 16.2; P = .00006). Using a binominal logistic regression model that adjusted for the number of doses of antiresorptive drug received, patients who received active dental input had an odds ratio of developing MRONJ of 0.24 (95% confidence interval, 0.09, 0.61; P = .004). The likelihood of developing MRONJ can be minimized through the implementation of prophylactic dental assessment and active dental intervention. This reinforces the importance of increased dental awareness and enhanced dental intervention in the prevention of MRONJ. CONTEXTMedication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to MRONJ and the challenges associated with its management, prevention is crucial.OBJECTIVEWe sought to evaluate the effectiveness of an active dental intervention in reducing MRONJ incidence.DESIGN AND SETTINGWe identified all patients who received antiresorptive drug therapy at a specialized cancer center between January 2003 and December 2013 through hospital pharmacy records, whereas confirmed cases of MRONJ were identified through a hospital database.MAIN OUTCOME MEASURESThe incidence of MRONJ before and after the implementation of active dental intervention in July 2008 was quantified and compared.RESULTSA total of 1243 patients received antiresorptive drug therapy, with 34 confirmed cases of MRONJ (crude overall incidence, 2.7%). The incidence of MRONJ was significantly lower in patients who received antiresorptive therapy after the implementation of guidelines that emphasized active dental input (0.8 vs 4.6%; χ(2) = 16.2; P = .00006). Using a binominal logistic regression model that adjusted for the number of doses of antiresorptive drug received, patients who received active dental input had an odds ratio of developing MRONJ of 0.24 (95% confidence interval, 0.09, 0.61; P = .004).CONCLUSIONThe likelihood of developing MRONJ can be minimized through the implementation of prophylactic dental assessment and active dental intervention. This reinforces the importance of increased dental awareness and enhanced dental intervention in the prevention of MRONJ. |
Author | Sim, Ie-Wen Borromeo, Gelsomina L Seymour, John F Ebeling, Peter R Sanders, Kerrie M |
AuthorAffiliation | Western Campus, Melbourne Medical School (I.-W.S., K.M.S.), University of Melbourne, St Albans, Victoria 3021, Australia; Department of Endocrinology (I.-W.S.), Western Health, Melbourne, Victoria 3021, Australia; Department of Endocrinology (I.-W.S., P.R.E.), Monash Health, Melbourne, Victoria 3168, Australia; Institute of Health and Ageing (K.M.S.), Australian Catholic University, Melbourne, Victoria 3000, Australia; Melbourne Dental School (G.L.B.), University of Melbourne, Carlton, Victoria 3053, Australia; Department of Haematology (J.F.S.), Peter MacCallum Cancer Centre, Melbourne, and University of Melbourne, East Melbourne, Victoria 3002, Australia; and Department of Medicine (P.R.E.), School of Clinical Sciences, Monash University, Melbourne, Victoria 3168, Australia |
AuthorAffiliation_xml | – name: Western Campus, Melbourne Medical School (I.-W.S., K.M.S.), University of Melbourne, St Albans, Victoria 3021, Australia; Department of Endocrinology (I.-W.S.), Western Health, Melbourne, Victoria 3021, Australia; Department of Endocrinology (I.-W.S., P.R.E.), Monash Health, Melbourne, Victoria 3168, Australia; Institute of Health and Ageing (K.M.S.), Australian Catholic University, Melbourne, Victoria 3000, Australia; Melbourne Dental School (G.L.B.), University of Melbourne, Carlton, Victoria 3053, Australia; Department of Haematology (J.F.S.), Peter MacCallum Cancer Centre, Melbourne, and University of Melbourne, East Melbourne, Victoria 3002, Australia; and Department of Medicine (P.R.E.), School of Clinical Sciences, Monash University, Melbourne, Victoria 3168, Australia |
Author_xml | – sequence: 1 givenname: Ie-Wen surname: Sim fullname: Sim, Ie-Wen email: simi@unimelb.edu.au – sequence: 2 givenname: Kerrie M surname: Sanders fullname: Sanders, Kerrie M – sequence: 3 givenname: Gelsomina L surname: Borromeo fullname: Borromeo, Gelsomina L – sequence: 4 givenname: John F surname: Seymour fullname: Seymour, John F – sequence: 5 givenname: Peter R surname: Ebeling fullname: Ebeling, Peter R |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26241323$$D View this record in MEDLINE/PubMed |
BookMark | eNptkE2PFCEQholZ486u3jwbjh5k5avp4Whm_VizZo3RaLwQGqodxh4Ygc7Efy-dWT1JUiEkT71FPRfoLKYICD1l9IpxRl_u3BWnrCOs1_IBWjEtO9Iz3Z-hFaWcEd3zb-foopQdpUzKTjxC51xxyQQXK_T9GtwUYog_8E10wUN0gNOIP4APztaQIvkEk63g8V2p0Ea7nEooC1O3gN_bIw4Rf2woxFrw11C3eGNbSn6MHo52KvDk_r5EX968_rx5R27v3t5sXt0SJ6VUZOgVd3ropHJqLdeSW0EF1dzZtQM_cj9qqZUYfUcHGJTjA9MdeOekdloILy7R81PuIadfM5Rq9qE4mCYbIc3FsJ5T2XGpZUNfnNBliZJhNIcc9jb_NoyaxabZObPYNIvNhj-7T56HPfh_8F99DZAn4JimCrn8nOYjZLMFO9Wtoe1I1a_JksiWF2klVGsTpzaIPrkcIhwylGJ2ac6xqfr_b_4ALMyR4g |
CitedBy_id | crossref_primary_10_1038_s41368_020_00093_2 crossref_primary_10_1002_JPER_21_0611 crossref_primary_10_1016_j_ajoms_2017_08_004 crossref_primary_10_1016_j_jfma_2021_01_015 crossref_primary_10_1186_s12913_024_10859_7 crossref_primary_10_1097_GME_0000000000001393 crossref_primary_10_1185_03007995_2016_1170005 crossref_primary_10_3390_dj4040032 crossref_primary_10_1007_s11838_023_00176_w crossref_primary_10_1016_j_clgc_2018_05_003 crossref_primary_10_1210_jc_2018_01965 crossref_primary_10_1016_j_jsps_2020_05_004 crossref_primary_10_3238_arztebl_2017_0063 crossref_primary_10_1016_j_bone_2021_115866 crossref_primary_10_1111_odi_12966 crossref_primary_10_1200_JCO_19_01186 crossref_primary_10_1200_JCO_19_02192 crossref_primary_10_1016_j_sdentj_2022_01_003 crossref_primary_10_1007_s12285_016_0063_4 crossref_primary_10_1111_odi_12842 crossref_primary_10_3390_medicina59030535 crossref_primary_10_1097_SCS_0000000000009033 crossref_primary_10_1200_JCO_20_01633 crossref_primary_10_1007_s00774_020_01195_x crossref_primary_10_1007_s00520_022_06839_4 crossref_primary_10_1016_j_ctrv_2018_06_007 crossref_primary_10_1007_s11428_017_0235_5 crossref_primary_10_1200_JOP_19_00384 crossref_primary_10_32388_MZJDOX crossref_primary_10_1016_j_bone_2020_115412 crossref_primary_10_1177_0192623317737066 |
ContentType | Journal Article |
Copyright | Copyright © 2015 by the Endocrine Society Copyright © 2015 by The Endocrine Society |
Copyright_xml | – notice: Copyright © 2015 by the Endocrine Society – notice: Copyright © 2015 by The Endocrine Society |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1210/jc.2015-1794 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1945-7197 |
EndPage | 3893 |
ExternalDocumentID | 10_1210_jc_2015_1794 26241323 00004678-201510000-00036 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - 02 08R 0R 1TH 29K 2WC 34G 39C 3O- 3V. 4.4 48X 53G 55 5GY 5RS 5YH 7X7 88E 8F7 8FI 8FJ AABJS AABMN AAIMJ AAJQQ AAPQZ AAQQT AAUQX AAWTL AAYJJ ABFLS ABOCM ABPMR ABPPZ ABSAR ABUWG ACGFS ACIMA ACPRK ACUTJ ADBBV ADBIT ADEIU ADGZP ADHKW ADRTK AELNO AELWJ AEMDU AENEX AENZO AETBJ AEWNT AFCHL AFFNX AFKRA AFRAH AFXEN AGINJ AGKRT AGVJH AHMBA AIKOY AIMBJ ALMA_UNASSIGNED_HOLDINGS APIBT AQKUS ARIXL ASMCH ASPBG AVWKF AYOIW AZFZN AZQFJ BAWUL BAYMD BBAFP BCRHZ BENPR BEYMZ BGYMP BHONS BPHCQ BSWAC BTRTY BVXVI C45 CDBKE CS3 D-I DAKXR DIK DPPUQ E3Z EBS EIHJH EJD ENERS F5P FEDTE FH7 FHSFR FOTVD FQBLK FYUFA G8K GAUVT GJ GJXCC GX1 H1 H13 HVGLF HZ H~9 IAO IHR INH J5H KBUDW KOP KQ8 KSN L7B M1P M5 MBLQV MHKGH N9A NLBLG NOYVH NVLIB O0- O9- OBH OCB ODMLO OGEVE OK1 OVD P2P PQEST PQQKQ PQUKI PRINS PROAC PSQYO REU ROX ROZ TCN TJX TLC TMA TWZ VH1 WOQ X X52 X7M XZ ZA5 ZGI ZXP ZY1 .XZ 3RD AJYGW M2M M5~ ROL ~H1 --- -~X .55 .GJ 08P 0R~ 18M 354 AABZA AACZT AAKAS AAPGJ AAPXW AARHZ AAUAY AAVAP AAWDT ABBLC ABJNI ABLJU ABMNT ABNHQ ABPQP ABPTD ABQNK ABWST ABXVV ACFRR ACGFO ACYHN ACZBC ADGKP ADQBN ADVEK ADZCM AERZD AFFZL AFGWE AFOFC AFXAL AFYAG AGMDO AGQXC AGUTN AI. AJEEA APJGH AQDSO ATGXG AVNTJ CGR CUY CVF ECM EIF EMOBN FECEO FLUFQ FOEOM HZ~ ITC KSI MJL N4W NOMLY NPM OAUYM OFXIZ OHH OJZSN OPAEJ OVIDX P6G TEORI TR2 VVN W8F WHG YBU YFH YHG YOC YSK ~02 AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c4446-b762c9b546c684842a303092ca8cedf2df94963fd50beb6c2b195edcc49c933d3 |
ISSN | 0021-972X |
IngestDate | Fri Aug 16 21:50:44 EDT 2024 Thu Sep 26 18:32:35 EDT 2024 Sat Sep 28 08:03:23 EDT 2024 Thu Aug 13 19:54:33 EDT 2020 Tue Jan 05 21:44:44 EST 2021 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4446-b762c9b546c684842a303092ca8cedf2df94963fd50beb6c2b195edcc49c933d3 |
Notes | The National Health and Medical Research Council of Australia supports I.-W.S. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://academic.oup.com/jcem/article-pdf/100/10/3887/10424467/jcem3887.pdf |
PMID | 26241323 |
PQID | 1720452494 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1720452494 crossref_primary_10_1210_jc_2015_1794 pubmed_primary_26241323 wolterskluwer_health_00004678-201510000-00036 endocrinepress_journals_10_1210_jc_2015_1794 |
ProviderPackageCode | .XZ OBH C45 5RS AFCHL OGEVE ~H1 ABPMR M5~ OVD OCB |
PublicationCentury | 2000 |
PublicationDate | 2015-October |
PublicationDateYYYYMMDD | 2015-10-01 |
PublicationDate_xml | – month: 10 year: 2015 text: 2015-October |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The journal of clinical endocrinology and metabolism |
PublicationTitleAlternate | J Clin Endocrinol Metab |
PublicationYear | 2015 |
Publisher | Endocrine Society Copyright by The Endocrine Society |
Publisher_xml | – name: Endocrine Society – name: Copyright by The Endocrine Society |
References | López-Jornet, P; Camacho-Alonso, F; Martínez-Canovas, A; Molina-Miñano, F; Gómez-García, F; Vicente-Ortega, V (B30) 2011; 69 Marx, RE (B20) 2003; 61 Coxon, FP; Thompson, K; Rogers, MJ (B26) 2006; 6 Miksad, RA; Lai, KC; Dodson, TB (B12) 2011; 16 Van den Wyngaert, T; Huizing, MT; Fossion, E; Vermorken, JB (B17) 2009; 14 La Verde, N; Bareggi, C; Garassino, M (B25) 2008; 16 Wilkinson, GS; Kuo, YF; Freeman, JL; Goodwin, JS (B9) 2007; 99 Boonyapakorn, T; Schirmer, I; Reichart, PA; Sturm, I; Massenkeil, G (B21) 2008; 44 Dimopoulos, MA; Kastritis, E; Bamia, C (B23) 2009; 20 Khosla, S; Burr, D; Cauley, J (B1) 2007; 22 (B15) 2007; 65 Maerevoet, M; Martin, C; Duck, L (B28) 2005; 353 Hoff, AO; Toth, BB; Altundag, K (B3) 2008; 23 Tsao, C; Darby, I; Ebeling, PR (B10) 2013; 71 Mavrokokki, T; Cheng, A; Stein, B; Goss, A (B22) 2007; 65 Sambrook, PJ; Nordin, BE; Goss, AN (B11) 2011; 194 Ripamonti, CI; Maniezzo, M; Campa, T (B24) 2009; 20 Ruggiero, SL; Dodson, TB; Fantasia, J (B2) 2014; 72 Santini, D; Fratto, ME; Vincenzi, B; La Cesa, A; Dianzani, C; Tonini, G (B18) 2004; 18 Cheung, A; Seeman, E (B13) 2010; 363 Raj, DV; Abuzar, M; Borromeo, GL (B14) Stopeck, AT; Lipton, A; Body, JJ (B29) 2010; 28 Durie, BG; Katz, M; Crowley, J (B5) 2005; 353 Fizazi, K; Carducci, M; Smith, M (B7) 2011; 377 Ruggiero, SL; Dodson, TB; Assael, LA; Landesberg, R; Marx, RE; Mehrotra, B (B16) 2009; 67 Dickinson, M; Prince, HM; Kirsa, S (B8) 2009; 39 Santini, D; Vespasiani Gentilucci, U; Vincenzi, B (B19) 2003; 14 Fleisch, H (B27) 1998; 19 Mawardi, H; Giro, G; Kajiya, M (B31) 2011; 90 Hoff, AO; Toth, B; Hu, M; Hortobagyi, GN; Gagel, RF (B4) 2011; 1218 Henry, DH; Costa, L; Goldwasser, F (B6) 2011; 29 |
References_xml | – ident: B14 article-title: Bisphosphonates, healthcare professionals and oral health [published online July 15, 2014] publication-title: Gerodontology contributor: fullname: Raj, DV; Abuzar, M; Borromeo, GL – volume: 14 start-page: 181 year: 2009 end-page: 191 ident: B17 article-title: Bisphosphonates in oncology: rising stars or fallen heroes publication-title: Oncologist contributor: fullname: Van den Wyngaert, T; Huizing, MT; Fossion, E; Vermorken, JB – volume: 16 start-page: 121 year: 2011 end-page: 132 ident: B12 article-title: Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw publication-title: Oncologist contributor: fullname: Miksad, RA; Lai, KC; Dodson, TB – volume: 99 start-page: 1016 year: 2007 end-page: 1024 ident: B9 article-title: Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis publication-title: J Natl Cancer Inst contributor: fullname: Wilkinson, GS; Kuo, YF; Freeman, JL; Goodwin, JS – volume: 71 start-page: 1360 year: 2013 end-page: 1366 ident: B10 article-title: Oral health risk factors for bisphosphonate-associated jaw osteonecrosis publication-title: J Oral Maxillofac Surg contributor: fullname: Tsao, C; Darby, I; Ebeling, PR – volume: 67 start-page: 2 year: 2009 end-page: 12 ident: B16 article-title: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws–2009 update publication-title: J Oral Maxillofac Surg contributor: fullname: Ruggiero, SL; Dodson, TB; Assael, LA; Landesberg, R; Marx, RE; Mehrotra, B – volume: 20 start-page: 117 year: 2009 end-page: 120 ident: B23 article-title: Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid publication-title: Ann Oncol contributor: fullname: Dimopoulos, MA; Kastritis, E; Bamia, C – volume: 22 start-page: 1479 year: 2007 end-page: 1491 ident: B1 article-title: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research publication-title: J Bone Miner Res contributor: fullname: Khosla, S; Burr, D; Cauley, J – volume: 44 start-page: 857 year: 2008 end-page: 869 ident: B21 article-title: Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies publication-title: Oral Oncol contributor: fullname: Boonyapakorn, T; Schirmer, I; Reichart, PA; Sturm, I; Massenkeil, G – volume: 16 start-page: 1311 year: 2008 end-page: 1315 ident: B25 article-title: Osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates: how the knowledge of a phenomenon can change its evolution publication-title: Support Care Cancer contributor: fullname: La Verde, N; Bareggi, C; Garassino, M – volume: 363 start-page: 2473 year: 2010 end-page: 2474 ident: B13 article-title: Teriparatide therapy for alendronate-associated osteonecrosis of the jaw publication-title: N Engl J Med contributor: fullname: Cheung, A; Seeman, E – volume: 20 start-page: 137 year: 2009 end-page: 145 ident: B24 article-title: Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan publication-title: Ann Oncol contributor: fullname: Ripamonti, CI; Maniezzo, M; Campa, T – volume: 377 start-page: 813 year: 2011 end-page: 822 ident: B7 article-title: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study publication-title: Lancet contributor: fullname: Fizazi, K; Carducci, M; Smith, M – volume: 23 start-page: 826 year: 2008 end-page: 836 ident: B3 article-title: Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates publication-title: J Bone Miner Res contributor: fullname: Hoff, AO; Toth, BB; Altundag, K – volume: 19 start-page: 80 year: 1998 end-page: 100 ident: B27 article-title: Bisphosphonates: mechanisms of action publication-title: Endocr Rev contributor: fullname: Fleisch, H – volume: 65 start-page: 369 year: 2007 end-page: 376 ident: B15 article-title: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws publication-title: J Oral Maxillofac Surg – volume: 1218 start-page: 47 year: 2011 end-page: 54 ident: B4 article-title: Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients publication-title: Ann NY Acad Sci contributor: fullname: Hoff, AO; Toth, B; Hu, M; Hortobagyi, GN; Gagel, RF – volume: 14 start-page: 1468 year: 2003 end-page: 1476 ident: B19 article-title: The antineoplastic role of bisphosphonates: from basic research to clinical evidence publication-title: Ann Oncol contributor: fullname: Santini, D; Vespasiani Gentilucci, U; Vincenzi, B – volume: 29 start-page: 1125 year: 2011 end-page: 1132 ident: B6 article-title: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma publication-title: J Clin Oncol contributor: fullname: Henry, DH; Costa, L; Goldwasser, F – volume: 18 start-page: 269 year: 2004 end-page: 278 ident: B18 article-title: Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities publication-title: BioDrugs contributor: fullname: Santini, D; Fratto, ME; Vincenzi, B; La Cesa, A; Dianzani, C; Tonini, G – volume: 6 start-page: 307 year: 2006 end-page: 312 ident: B26 article-title: Recent advances in understanding the mechanism of action of bisphosphonates publication-title: Curr Opin Pharmacol contributor: fullname: Coxon, FP; Thompson, K; Rogers, MJ – volume: 353 start-page: 99 year: 2005 ident: B5 article-title: Osteonecrosis of the jaw and bisphosphonates publication-title: N Engl J Med contributor: fullname: Durie, BG; Katz, M; Crowley, J – volume: 39 start-page: 304 year: 2009 end-page: 316 ident: B8 article-title: Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment publication-title: Intern Med J contributor: fullname: Dickinson, M; Prince, HM; Kirsa, S – volume: 69 start-page: 2488 year: 2011 end-page: 2493 ident: B30 article-title: Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws publication-title: J Oral Maxillofac Surg contributor: fullname: López-Jornet, P; Camacho-Alonso, F; Martínez-Canovas, A; Molina-Miñano, F; Gómez-García, F; Vicente-Ortega, V – volume: 194 start-page: 51 year: 2011 end-page: 52 ident: B11 article-title: Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality publication-title: Med J Aust contributor: fullname: Sambrook, PJ; Nordin, BE; Goss, AN – volume: 90 start-page: 1339 year: 2011 end-page: 1345 ident: B31 article-title: A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw publication-title: J Dent Res contributor: fullname: Mawardi, H; Giro, G; Kajiya, M – volume: 353 start-page: 100 year: 2005 end-page: 101 ident: B28 article-title: Osteonecrosis of the jaw and bisphosphonates publication-title: N Engl J Med contributor: fullname: Maerevoet, M; Martin, C; Duck, L – volume: 65 start-page: 415 year: 2007 end-page: 423 ident: B22 article-title: Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia publication-title: J Oral Maxillofac Surg contributor: fullname: Mavrokokki, T; Cheng, A; Stein, B; Goss, A – volume: 28 start-page: 5132 year: 2010 end-page: 5139 ident: B29 article-title: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study publication-title: J Clin Oncol contributor: fullname: Stopeck, AT; Lipton, A; Body, JJ – volume: 61 start-page: 1115 year: 2003 end-page: 1117 ident: B20 article-title: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic publication-title: J Oral Maxillofac Surg contributor: fullname: Marx, RE – volume: 72 start-page: 1938 year: 2014 end-page: 1956 ident: B2 article-title: American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update publication-title: J Oral Maxillofac Surg contributor: fullname: Ruggiero, SL; Dodson, TB; Fantasia, J |
SSID | ssj0014453 |
Score | 2.410548 |
Snippet | Context:
Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity... CONTEXT:Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable... Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to... CONTEXTMedication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable... |
SourceID | proquest crossref pubmed wolterskluwer endocrinepress |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 3887 |
SubjectTerms | Adult Aged Aged, 80 and over Bisphosphonate-Associated Osteonecrosis of the Jaw - epidemiology Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - therapeutic use Dental Care - methods Female Humans Incidence Male Middle Aged Neoplasms - drug therapy Retrospective Studies |
Title | Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer |
URI | http://dx.doi.org/10.1210/jc.2015-1794 http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201510000-00036 https://www.ncbi.nlm.nih.gov/pubmed/26241323 https://search.proquest.com/docview/1720452494 |
Volume | 100 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9RAFB7WCmJR8e56YwR90pFcZpLMo1qlrVSFtlh8CZlLwFoTye5S8Ef5Gz1nZpLN2hWsLIQkHDKzOV9mzv0Q8jQ3uorTOmOZ0JLxKslZpSIDZzo1MpY2ijHfee9Dtn3Id4_E0WTyaxS1tJirl_rn2ryS_-Eq3AO-YpbsOTg7PBRuwDnwF47AYTj-E4-3rEtsdD5_7buDupAW53zBYZmLdQOZ8iMws20s7om-AAnKm7vVKZo7PvnSqhgJ6xKS4CndWGZFJI0KTAy5lLYxLaw5zbKK03c7B0yd9FUJ0XDjmzXvWPZ5mXO27zNqfFpQB7r60iT7uu2wfkLrzfUnsxYjdZ4PBup9i6aKro8hDmHJwWgRiyH8LVjSwgRtH5s6XqIxZiR3PdZhg_KrsuSC5bEP5B2W7Sga4zMarcJpETZxGy59E8YzuwWou7hbYCVLnGLu2y3_UX8btSQgLI91iWQlkl0gF5NcClT2t3beD14rzkPV0_AXQqIFZkmNB1kRga72zPKBz-sUnU1y5bTF2InZN5c6MRKADq6Ta0Fzoa88DG-QiW1ukkt7ITbjFvkyoJEOaKRtTc-ika6gEWkAjRTQSL82tEcjRTRSj8bb5PDd24M32yx07mCac54xBVuslkrwTGcFL3hSpejKS3RVaGvqxNSSw8pfGxEpqzKdqFgKa7TmUss0NekdstHAPO4RymWhUGYvTKS5KXKpCi4Vt7XIdAy_KXnWv8zyhy_QUq5j2ZS8WH3TZfhyZn8hf9LzoYQFF71oVWPbBVBjWyeRcKS56xk0DJxk6KZO0ilhKxwrfVJz6TRyEA8ZjuM8a8xVhLp_vsk9IJeXH9VDsjHvFvYRyMZz9dgB8jfoJrlO |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Declining+Incidence+of+Medication-Related+Osteonecrosis+of+the+Jaw+in+Patients+With+Cancer&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Sim%2C+Ie-Wen&rft.au=Sanders%2C+Kerrie+M&rft.au=Borromeo%2C+Gelsomina+L&rft.au=Seymour%2C+John+F&rft.date=2015-10-01&rft.pub=Endocrine+Society&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=100&rft.issue=10&rft.spage=3887&rft.epage=3893&rft_id=info:doi/10.1210%2Fjc.2015-1794&rft.externalDocID=10_1210_jc_2015_1794 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |